At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Pemigatinibdrug
Likely dose
Pemigatinib 13.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210)
In Brief
A Phase 2 clinical trial evaluating Pemigatinib for Non-Small Cell Lung Cancer (NSCLC). Completed, enrolled 8 participants across 36 sites in 5 countries.
Detailed Summary
This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer (NSCLC)
CountriesFrance, Germany, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionAug 2023
TodayJul 2026
First PostedFeb 24, 2022
Enrollment StartApr 29, 2022
Primary CompletionAug 16, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.4 years ago
Interventions
Pemigatinibdrug
13.5 mg tablet